TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05663151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Description: Participation will occur throughout 17 weeks over 15 separate visits during which 10, 60-minute sessions of PE will take place. Session 1 of PE will focus on psychoeducation. Session 2 of PE will involve a continuation of psychoeducation and rationale for exposure as well as the collaborative construction of the in vivo exposure hierarchy. After session 2, participants will begin homework where they are instructed to confront situations on their hierarchy. Starting in session 3 of PE, participants will begin imaginal exposures to their worst trauma memory. This involves the participant recounting and visualizing the trauma memory aloud with the clinician in the room for 30-40 minutes. The session will end with 15-20 minutes of processing the imaginal exposure. Participants will continue in-session imaginal exposures until the end of treatment. Throughout the treatment, participants will listen to a recording of their imaginal exposure and engage in in vivo exposures daily.
Study: NCT06760286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lung Care Solution
Description: Participants in the Breathe-Easy group received the food supplement solution designed to improve lung health and respiratory function. The supplement includes natural ingredients known for their potential to reduce inflammation, improve oxygen utilization, and support overall lung capacity.~Participants used 1 teaspoon of the supplement, prepared as a tea decoction, twice daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support treatment
Description: Participants in this group engaged in guided lifestyle modifications aimed at improving respiratory health. This included dietary recommendations as part of clinical practice.
Study: NCT06108258

Intervention type: DRUG
Intervention: IV iron administration
Description: IV iron administration during pregnancy
Study: NCT05396664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATWA
Description: The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
Study: NCT05711342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggression
Description: The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
Study: NCT06205706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1910
Description: BI-1910 administered as a flat-dose IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1910
Description: BI-1910 administered as a flat-dose IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1910
Description: BI-1910 administered as a flat-dose IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1910
Description: BI-1910 administered as a flat-dose IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
Study: NCT06132633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neospot vitals measurement
Description: Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
Study: NCT04288479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single high-intensity interval training session
Description: 10 minutes warming up at low-to-moderate intensity, 8x30 seconds high intensity interval training with fetal heart rate measurement after each 30 second work-bout, 2 minutes recovery at low-to-moderate intensity. Continuous monitoring of maternal heart rate.
Study: NCT04529278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is initiated at 0.6 mg / day during week S1 (initiation D1) during weekly hospitalization in the diabetology department. Then the dose of liraglutide is increased to 1.2 mg / day on week S2 (increase in dose on D8) then to 1.8 mg / day on week S3 (increase in dose on D15).~The daily dose is then 1.8 mg until week W26.
Study: NCT05518175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional laparoscopy
Description: Utilizes three or four 5 mm ports for access and retrieval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single site laparoscopy
Description: One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Notes surgery
Description: One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
Study: NCT05359237

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Intervention: Vincristine
Description: Given IV per standard of care
Study: NCT05853601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose Theophylline
Description: Subjects are given a single loading dose of theophylline, 5mg/kg IV, within 18 hours after birth. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeat Dose Theophylline
Description: Subjects are given a loading dose of theophylline, 5mg/kg IV, within 18 hours of birth, and then two subsequent doses (1.2mg/kg iv) at 12 hours and 24 hours after loading dose. A bioequivalent dose of aminophylline, a more soluble, ethylenediamine salt of theophylline, may be substituted for theophylline. The bioequivalent dose of aminophylline is 120% of the theophylline dose.
Study: NCT04911426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: The telehealth intervention is delivered with an app developed for this research. The intervention features live video calling, messaging, appointment reminders; clinical support is provided by licensed clinicians.
Study: NCT06460636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progressive muscle relaxation therapy
Description: Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation therapy
Description: Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
Study: NCT05537389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line filter
Description: All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.
Study: NCT06221462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
Study: NCT06460636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
Study: NCT06266780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPTS Enhanced Family Planning Counselling
Description: Based on a targeted human-centered-design process with pregnant and early postpartum mothers, the intervention consists of informative messages, counselling and reminders regarding postpartum family planning and birth spacing, leveraging an existing mobile health platform (PROMPTS) for intervention delivery and Jacaranda's established partnership with the Kenyan Ministry of Health, county health offices and public maternity hospitals method options. The intervention includes several features: activation of family planning discussions between pregnant and postpartum women and their health care providers, information provision, method selection support to help women choose their preferred method, and reminders to follow-up. The key feature is to help women make an informed plan about family planning in the prenatal or early postpartum period and follow through with this plan.
Study: NCT06210334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg, iv, d3, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
Study: NCT05442294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Juego de Llaves
Description: The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
Study: NCT06261372

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The mindfulness meditation combined with progressive muscle relaxation training .
Description: The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.
Study: NCT04625322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV care provided by hospitalist during acute psychiatric admission
Description: HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
Study: NCT05112419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
Study: NCT05716945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone 0.1% Oph Susp
Description: Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% Oph Susp
Description: Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1% ophthalmic suspension
Description: Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% ophthalmic suspension
Description: Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop steroids
Description: Half the patients in each study arm will discontinue steroids.
Study: NCT06426979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: FEMARA 2.5 mg tablets two tablets daily
Study: NCT04719156

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine green solution administered at 2.0mg/kg.
Description: Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Stryker SPY-PHI Imaging Device
Description: The SPY-PHI system is used with the ICG dye to provide fluorescence images.
Study: NCT04682665

Intervention type: DRUG
Intervention: Icosapent Ethyl Oral Capsule
Description: Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.

Intervention type: OTHER
Intervention: Placebo
Description: Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
Study: NCT05123326

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.

Intervention type: DIAGNOSTIC_TEST
Intervention: Rotational thromboelastometry
Description: ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic tests for Thrombophilia
Description: Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic tests for Thrombophilia
Description: Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA tests/ Functional assays
Description: Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA tests/ Functional assays
Description: Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
Study: NCT04580251

Intervention type: PROCEDURE
Intervention: Targeted axillary dissection
Description: The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
Study: NCT05053191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership, Assessment, Care and Transition training intervention
Description: Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
Study: NCT06148246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Fit Condition
Description: Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only Condition
Description: Dyads in the Fitbit only condition will use a Fitbit and the Fitbit app for 18 weeks, working to increase their moderate- to vigorous-intensity physical activity.
Study: NCT04580251

Intervention type: PROCEDURE
Intervention: Targeted axillary dissection
Description: The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)

Intervention type: PROCEDURE
Intervention: Targeted axillary dissection
Description: The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
Study: NCT04409912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated balloon
Description: Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plain balloon
Description: Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
Study: NCT06422650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa capsule 500mg
Description: Nigella Sativa capsule 500mg twice daily for 8 weeks
Study: NCT05739188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GPRC5D CAR-T cells infusion
Description: This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%.
Study: NCT04882709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver-in-canal hearing aid 1 default
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver-in-canal hearing aid 2
Description: A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing aid 1 strategy 1
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing aid 1 strategy 2
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
Study: NCT06422650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin
Study: NCT05759845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 25Mg Tab
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline 25 Mg Oral Tablet
Description: Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate 25mg plus amitriptyline 25mg
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
Study: NCT06451718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracorneal implantation
Description: Intracorneal implantation of the nitinol investigational device
Study: NCT03513042

Intervention type: RADIATION
Intervention: Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy
Description: Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)
Study: NCT04270643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: ATC code A11CC05 (cholecalciferol)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ethyl oleate